Latest Operating Expenses News

Nutritional Growth Solutions reported a slight revenue decline in Q4 FY24 but remains optimistic about growth and profitability in FY25, buoyed by renewed Walmart partnerships and expanding Asian distribution.

HALO Technologies reports a robust 45.5% increase in operating revenue for 2024, driven by surging Funds Under Management and brokerage income, while advancing its UK market entry alongside a $6.75 million capital raise.

Purifloh Limited has made significant progress in its PFAS destruction technology, securing a $100,000 BRII feasibility grant while navigating challenges to resume trading on the ASX.

Rare Foods Australia reports an 18% biomass increase and $440k in cost savings, while launching its Subsea Estate brand and securing a $2.1M R&D refund to support growth.

RooLife Group (ASX: RLG) reported a striking 144% increase in sales revenue for Q2 FY2025, driven by the launch of new online stores across China, Hong Kong, Australia, and India. The company is investing heavily in product development and marketing to capitalize on booming health and wellness markets.

Tombador Iron Limited reported a modest net cash outflow of $317,000 for the December 2024 quarter, yet holds robust cash reserves of $10.825 million, underpinning over 34 quarters of operational funding.

Fatfish Group reported a 20% increase in cash receipts to A$0.76 million for Q4 2024, driven by advances in its AI gaming subsidiary, but rising operating expenses led to a net cash outflow of A$0.37 million.

iCandy Interactive reports a remarkable 105% increase in net cash flow for Q4 2024 despite a 22% drop in cash receipts, driven by strategic expansions and operational efficiencies amid ongoing legal disputes.

FinTech Chain Limited reports a robust increase in cash balances and positive operating cash flow for Q3 2024, alongside new contract wins and ongoing legal proceedings related to a past misappropriation case.

True North Copper Limited reported a significant cash outflow in the December 2024 quarter, driven by high operating expenses linked to voluntary administration and exploration activities. Despite ending the quarter with $19.12 million in cash, the company’s negative operating cash flow signals ongoing financial pressure.

Vectus Biosystems reports completion of Phase Ib trials for its lead drug VB0004 and a robust cash position bolstered by a significant R&D tax refund, setting the stage for licensing discussions.

Peninsula Energy Limited reported a substantial cash outflow in the December 2024 quarter, driven by significant investing activity related to its Lance Projects. The company is actively pursuing additional funding to support upcoming production scale-up.